+950.8%
MU vs MRNA
+221.0%
+729.9%
-57.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.5% | -3.4% | +0.9% | -2.3% |
| 7D | +12.8% | -12.1% | +24.9% | +13.8% |
| 30D | -14.9% | -1.3% | -13.6% | -14.8% |
| 3M | -18.0% | +250.9% | -269.0% | -29.7% |
| 6M | -3.1% | +343.0% | -346.1% | -23.5% |
| YTD | +172.9% | +657.4% | -484.5% | +85.1% |
| 1Y | +228.8% | +794.9% | -566.1% | +113.7% |
| 3Y | +950.8% | +218.1% | +732.7% | +632.9% |
| All | +950.8% | +221.0% | +729.9% | +632.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling